dr. matulonis discusses niraparib/pembrolizumab combo in platinum-resistant ovarian cancer
Published 6 years ago • 689 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
2:16
dr. matulonis discusses mirvetuximab soravtansine plus pembrolizumab in ovarian cancer
-
0:58
dr. matulonis on individualized dosing of niraparib in ovarian cancer
-
1:47
dr. matulonis on the nova trial of niraparib maintenance therapy in ovarian cancer
-
1:37
dr. matulonis discusses maintenance in ovarian cancer
-
1:25
dr. matulonis on final data from keynote-100 in recurrent ovarian cancer
-
2:25
results of niraparib/bevacizumab combo in platinum-sensitive recurrent ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
1:09
dr. arend on unmet needs in platinum-resistant ovarian cancer
-
1:06
dr. matulonis discusses rationale of quadra trial
-
1:44
dr. matulonis on the current treatment landscape in ovarian cancer
-
6:57
niraparib maintenance for recurrent ovarian cancer
-
3:08
ovarian cancer: optimizing treatment with niraparib
-
0:42
dr. zsiros discusses pembrolizumab triplet in recurrent ovarian cancer
-
1:15
introduction to keynote-100 trial of pembrolizumab in advanced recurrent ovarian cancer
-
6:40
keynote-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial